ASCO 2021 Highlights Podcast

 

In this podcast, Medicom’s correspondent covers 6 presentations held at the American Society of Clinical Oncology (ASCO21), held 4-8 June 2021. The topics discussed are:

1. Addition of ¹⁷⁷Lu-PSMA-617 therapy to standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improves survival, according to results from the randomised, phase 3 VISION trial.
2. First results of the randomised, phase 3 CheckMate-648 study demonstrate superior overall survival of first-line treatment with nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone for advanced or metastatic oesophageal squamous cell cancer.
3. A first interim analysis of the OlympiA trial demonstrates significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer after 1 year of adjuvant treatment with the PARP inhibitor olaparib.
4. First results of the phase 3 KEYNOTE-564 trial show that adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell renal cell cancer (RCC).
5. First results of the phase 3 RELATIVITY-047 trial validate the efficacy of dual checkpoint blockade demonstrated with the LAG-3 inhibitor relatlimab and nivolumab in patients with advanced melanoma.
6. In the phase 2 NANT2011-01 trial, levels of circulating tumour DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time.

Posted on 24 June 202127 June 2024